-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immunotherapy combined with antiangiogenic therapy for endometrial cancer is a promising therapeutic strategy
.
Recently, the journal J Immunother Cancer published the results of a phase II clinical study evaluating immune checkpoint inhibitors (nivolumab, nivolumab) in combination with anti-angiogenic drugs (cabozantinib, cabozantinib) in the treatment of patients without prior or Efficacy of immunotherapy in patients with endometrial cancer
Immunotherapy combined with antiangiogenic therapy for endometrial cancer is a promising therapeutic strategy
The researchers randomized patients with recurrent endometrial cancer in a 2:1 ratio to nivolumab in combination with cabozantinib (arm A) and nivolumab alone (arm B), with the primary endpoint being progression-free survival (PFS)
.
Patients with carcinosarcoma or prior immune checkpoint inhibitor therapy received combination therapy (group C)
The researchers randomized patients with recurrent endometrial cancer in a 2:1 ratio to nivolumab in combination with cabozantinib (arm A) and nivolumab alone (arm B), with the primary endpoint being progression-free survival (PFS)
Seventy-seven patients received treatment and were assessed for analysis: 36 in group A and 18 in group
B.
Median progression-free survival (PFS) was 5.
Seventy-seven patients received treatment and were assessed for analysis: 36 in group A and 18 in group
In the previous immunotherapy cohort (Group C; n=20), rechallenge with nivolumab in combination with cabozantinib resulted in an objective response in 5 patients (25%) and SD in 7 patients
.
Median SD duration was 5.
In the previous immunotherapy cohort (Group C; n=20), rechallenge with nivolumab in combination with cabozantinib resulted in an objective response in 5 patients (25%) and SD in 7 patients
Combination therapy is more prone to treatment-related toxicity than monotherapy
.
The most common treatment-related AEs in arm A were diarrhea, elevated liver enzymes, fatigue, and hypertension , with the exception of hypertension, which were usually grade 1/2
Combination therapy is more prone to treatment-related toxicity than monotherapy
Taken together, the study demonstrated that the addition of cabozantinib to nivolumab improved outcomes in patients with advanced endometrial cancer
.
.
Studies have shown that adding cabozantinib to nivolumab improves outcomes in patients with advanced endometrial cancer
.
Studies have shown that adding cabozantinib to nivolumab improves outcomes in patients with advanced endometrial cancer
.
Original source:
Original source:Lheureux S, Matei DE, Konstantinopoulos PA, et al.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Journal for ImmunoTherapy of Cancer 2022;0:e004233.
doi:10.
1136/jitc- 2021-004233.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Journal for ImmunoTherapy of Cancer 2022;0:e004233.
doi:10.
1136/jitc- 2021-004233.
Leave a message here